Endocrine Abstracts

Introduction: Several publications now demonstrate that growth hormone therapy in replacement doses does not increase the future risk of recurrence in brain tumours. However, there is less certainty about the best and safest time to start growth hormone (GH) therapy after completion of primary treatment with recent guidance suggesting that a delay of 1 year is appropriate. We plan to determine if the timing of GH initiation is related to the likelihood of tumour progression. <...